medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2024-27-49-55medalphabet-4060Research ArticleСтатьиВозможности МРТ всего тела в оценке распространенности злокачественного опухолевого процессаPossibilities of whole body MRI in assessing the prevalence of malignant tumor processhttps://orcid.org/0000-0002-8668-0945ПрохоровС. Н.ProkhorovS. N.

Прохоров Сергей Николаевич, врач-рентгенолог отделения радионуклидной диагностики № 1

Москва

Prokhorov Sergey N., radiologist at Dept of Radionuclide Diagnostics No. 1

Moscow

https://orcid.org/0000-0003-3381-0862КочергинаН. В.KocherginaN. V.

Кочергина Наталия Васильевна, д.м.н., научный консультант отделения рентгенодиагностики; проф. кафедры рентгенологии и радиологии

Москва 

Kochergina Natalia V., DM Sci (habil.), scientific consultant at Dept of Radionuclide Diagnostics; professor at Dept of Roentgenology and Radiology

Moscow

https://orcid.org/0000-0002-9571-801XРыжковА. Д.RyzhkovA. D.

Рыжков Алексей Дмитриевич, д.м.н., проф., врач-радиолог отделения радионуклидной диагностики № 1; ведущий научный сотрудник, врач-радиолог

Москва 

Ryzhkov Aleksey D., DM Sci (habil.), professor, radiologist at Dept of Radionuclide Diagnostics No. 1; leading researcher, radiologist

Moscow

adryzhkov60@yandex.ruhttps://orcid.org/0000-0002-8476-7879КрыловА. С.KrylovA. S.

Крылов Александр Сергеевич, к.м.н., доцент, зав. отделением радионуклидной диагностики № 1

Author ID: 723683. Scopus ID: 57192816516

Москва

Krylov Aleksandr S., PhD Med, associate professor, head of Dept of Radionuclide Diagnostics No 1

Author ID: 723683. Scopus ID: 57192816516

Moscow

 

krilovas@rambler.ruhttps://orcid.org/0000-0002-0970-6144БлудовА. Б.BludovA. B.

Блудов Александр Борисович, к.м.н., научный сотрудник

Москва

Bludov Alexander B., PhD Med, research fellow

Moscow

https://orcid.org/0000-0002-7954-2560НиколаеваЕ. А.NikolaevaE. A.

Николаева Екатерина Андреевна, аспирант, врач-радиолог отделения радионуклидной диагностики № 1 

Москва

Nikolaeva Ekaterina A., postgraduate student, radiologist at Dept of Radionuclide Diagnostics No. 1

Moscow

nikoka1901@gmail.comФГБУ «Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина» Минздрава РоссииРоссияN.N. Blokhin National Medical Investigation Centre of OncologyRussian FederationФГБУ «Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина» Минздрава России; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияN.N. Blokhin National Medical Investigation Centre of Oncology; Russian Medical Academy of Continuing Professional EducationRussian Federation202416122024027Диагностика и онкотерапия (3)4955Copyright © Прохоров С.Н., Кочергина Н.В., Рыжков А.Д., Крылов А.С., Блудов А.Б., Николаева Е.А., 20242024Прохоров С.Н., Кочергина Н.В., Рыжков А.Д., Крылов А.С., Блудов А.Б., Николаева Е.А.Prokhorov S.N., Kochergina N.V., Ryzhkov A.D., Krylov A.S., Bludov A.B., Nikolaeva E.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/4060Цель

Цель. Оценить возможности МРТ всего тела на основе последовательностей ускоренного сбора данных в оценке распространенности злокачественного опухолевого процесса.

Материалы и методы

Материалы и методы. В исследование вошли 30 пациентов со злокачественными, солидными опухолями различной природы и метастатическим поражением различных анатомических структур. Всем пациентам была проведена МРТ всего тела, основанная на последовательностях ускоренного сбора данных, с выполнением последующих уточняющих исследований, таких как КТ-АГ, ПЭТ/КТ, УЗИ, для подтверждения либо опровержения злокачественности выявленных изменений.

Результаты

Результаты. У 14 из 30 пациентов удалось выявить дополнительные локализации метастатического поражения с помощью МРТ, без учета костей скелета.

Заключение

Заключение. МРТ всего тела в современных условиях позволяет за относительно короткий промежуток времени собрать исчерпывающую информацию для стадирования опухолевого заболевания.

Purpose

Purpose. To evaluate the capabilities of whole-body MRI based on accelerated acquisition sequences in assessing the extent of malignancy.

Material and methods

Material and methods. The study included 30 patients with malignant, solid tumors of various origins and metastatic lesions of various anatomical structures. All patients underwent WB-MRI, based on accelerated data collection sequences, with subsequent clarifying studies, such as CT, PET/ CT, ultrasound to confirm or refute the malignancy of the detected changes.

Results

Results. In 14 out of 30 cases, it was possible to identify additional localizations of metastatic lesions, excluding skeletal bones.

Conclusion

Conclusion. In modern conditions, WB-MRI makes it possible to collect comprehensive information for staging a tumor disease in a relatively short period of time.

МРТ всего телаПЭТ/КТонкологияwhole body MRIPET/CToncologyReferencesKosmin M, Makris A, Joshi PV, Ah-See ML, Woolf D, Padhani AR. The addition of wholebody magnetic resonance imaging to body computerised tomography alters treatment decisions in patients with metastatic breast cancer. Eur. J. Cancer. 2017 May; 77: 109–116. DOI: 10.1016/j.ejca.2017.03.001. Epub 2017 Apr 5. PMID: 28390297.Kosmin M, Makris A, Joshi PV, Ah-See ML, Woolf D, Padhani AR. The addition of wholebody magnetic resonance imaging to body computerised tomography alters treatment decisions in patients with metastatic breast cancer. Eur. J. Cancer. 2017 May; 77: 109–116. DOI: 10.1016/j.ejca.2017.03.001. Epub 2017 Apr 5. PMID: 28390297.Wu F, Bernard S, Fayad LM, Ilaslan H, Messiou C, Moulopoulos LA, Mulligan ME. Updates and Ongoing Challenges in Imaging of Multiple Myeloma: AJR Expert Panel Narrative Review. AJR Am.J. Roentgenol. 2021 Oct; 217 (4): 775–785. DOI: 10.2214/AJR.21.25878. Epub 2021 May 12. PMID: 33978464.Wu F, Bernard S, Fayad LM, Ilaslan H, Messiou C, Moulopoulos LA, Mulligan ME. Updates and Ongoing Challenges in Imaging of Multiple Myeloma: AJR Expert Panel Narrative Review. AJR Am.J. Roentgenol. 2021 Oct; 217 (4): 775–785. DOI: 10.2214/AJR.21.25878. Epub 2021 May 12. PMID: 33978464.Trabulsi EJ, Rumble RB, Jadvar H. et al. Optimum imaging strategies for advanced prostate cancer: ASCO guideline. J. Clin. Oncol. 2020; 19: 02757.Trabulsi EJ, Rumble RB, Jadvar H. et al. Optimum imaging strategies for advanced prostate cancer: ASCO guideline. J. Clin. Oncol. 2020; 19: 02757.Lecouvet FE, El Mouedden J, Collette L, Coche E, Danse E, Jamar F, Machiels JP, Vande Berg B, Omoumi P, Tombal B. Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur. Urol. 2012 Jul; 62 (1): 68–75. DOI: 10.1016/j.eururo.2012.02.020. Epub 2012 Feb 17. PMID: 22366187.Lecouvet FE, El Mouedden J, Collette L, Coche E, Danse E, Jamar F, Machiels JP, Vande Berg B, Omoumi P, Tombal B. Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur. Urol. 2012 Jul; 62 (1): 68–75. DOI: 10.1016/j.eururo.2012.02.020. Epub 2012 Feb 17. PMID: 22366187.Schmidt GP, Baur-Melnyk A, Herzog P, Schmid R, Tiling R, Schmidt M, Reiser MF, Schoenberg SO. High-resolution whole-body magnetic resonance image tumor staging with the use of parallel imaging versus dual-modality positron emission tomography-computed tomography: experience on a 32-channel system. Invest Radiol. 2005 Dec; 40 (12): 743–53. DOI: 10.1097/01.rli.0000185878.61270.b0. PMID: 16304476.Schmidt GP, Baur-Melnyk A, Herzog P, Schmid R, Tiling R, Schmidt M, Reiser MF, Schoenberg SO. High-resolution whole-body magnetic resonance image tumor staging with the use of parallel imaging versus dual-modality positron emission tomography-computed tomography: experience on a 32-channel system. Invest Radiol. 2005 Dec; 40 (12): 743–53. DOI: 10.1097/01.rli.0000185878.61270.b0. PMID: 16304476.Schmidt GP, Baur-Melnyk A, Haug A, Heinemann V, Bauerfeind I, Reiser MF, Schoenberg SO. Comprehensive imaging of tumor recurrence in breast cancer patients using wholebody MRI at 1.5 and 3 T compared to FDG-PET-CT. Eur. J. Radiol. 2008 Jan; 65 (1): 47–58. DOI: 10.1016/j.ejrad.2007.10.021. Epub 2007 Dec 20. PMID: 18082989.Schmidt GP, Baur-Melnyk A, Haug A, Heinemann V, Bauerfeind I, Reiser MF, Schoenberg SO. Comprehensive imaging of tumor recurrence in breast cancer patients using wholebody MRI at 1.5 and 3 T compared to FDG-PET-CT. Eur. J. Radiol. 2008 Jan; 65 (1): 47–58. DOI: 10.1016/j.ejrad.2007.10.021. Epub 2007 Dec 20. PMID: 18082989.Ohno Y, Koyama H, Nogami M, Takenaka D, Yoshikawa T, Yoshimura M, Kotani Y, Nishimura Y, Higashino T, Sugimura K. Whole-body MR imaging vs. FDG-PET: comparison of accuracy of M-stage diagnosis for lung cancer patients. J. Magn. Reson. Imaging. 2007 Sep; 26 (3): 498–509. DOI: 10.1002/jmri.21031. PMID: 17729341.Ohno Y, Koyama H, Nogami M, Takenaka D, Yoshikawa T, Yoshimura M, Kotani Y, Nishimura Y, Higashino T, Sugimura K. Whole-body MR imaging vs. FDG-PET: comparison of accuracy of M-stage diagnosis for lung cancer patients. J. Magn. Reson. Imaging. 2007 Sep; 26 (3): 498–509. DOI: 10.1002/jmri.21031. PMID: 17729341.Conde-Moreno AJ, Herrando-Parreño G, Muelas-Soria R, Ferrer-Rebolleda J, Broseta-Torres R, Cozar-Santiago MP, García-Piñón F, Ferrer-Albiach C. Whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI) vs choline-positron emission tomography-computed tomography (choline-PET/CT) for selecting treatments in recurrent prostate cancer. Clin Transl Oncol. 2017 May; 19 (5): 553–561. DOI: 10.1007/s1209401615634. Epub 2016 Oct 31. PMID: 27796820.Conde-Moreno AJ, Herrando-Parreño G, Muelas-Soria R, Ferrer-Rebolleda J, Broseta-Torres R, Cozar-Santiago MP, García-Piñón F, Ferrer-Albiach C. Whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI) vs choline-positron emission tomography-computed tomography (choline-PET/CT) for selecting treatments in recurrent prostate cancer. Clin Transl Oncol. 2017 May; 19 (5): 553–561. DOI: 10.1007/s12094-016-1563-4. Epub 2016 Oct 31. PMID: 27796820.Gupta M, Choudhury PS, Hazarika D, Rawal S. A Comparative Study of 68Gallium-Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography and Magnetic Resonance Imaging for Lymph Node Staging in High Risk Prostate Cancer Patients: An Initial Experience. World J. Nucl. Med. 2017 Jul-Sep; 16 (3): 186–191. DOI: 10.4103/1450-1147.207272. PMID: 28670175; PMCID: PMC5460300.Gupta M, Choudhury PS, Hazarika D, Rawal S. A Comparative Study of 68Gallium-Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography and Magnetic Resonance Imaging for Lymph Node Staging in High Risk Prostate Cancer Patients: An Initial Experience. World J. Nucl. Med. 2017 Jul-Sep; 16 (3): 186–191. DOI: 10.4103/1450-1147.207272. PMID: 28670175; PMCID: PMC5460300.Villani A, Tabori U, Schiffman J, Shlien A, Beyene J, Druker H, Novokmet A, Finlay J, Malkin D. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncol. 2011 Jun; 12 (6): 559–67. DOI: 10.1016/S1470-2045(11)70119-X. Epub 2011 May 19. PMID: 21601526.Villani A, Tabori U, Schiffman J, Shlien A, Beyene J, Druker H, Novokmet A, Finlay J, Malkin D. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncol. 2011 Jun; 12 (6): 559–67. DOI: 10.1016/S1470-2045(11)70119-X. Epub 2011 May 19. PMID: 21601526.Monsalve J, Kapur J, Malkin D, Babyn PS. Imaging of cancer predisposition syndromes in children. Radiographics. 2011 Jan-Feb; 31 (1): 263–80. DOI: 10.1148/rg.311105099. Erratum in: Radiographics. 2011 Mar-Apr;31(2):624. PMID: 21257945.Monsalve J, Kapur J, Malkin D, Babyn PS. Imaging of cancer predisposition syndromes in children. Radiographics. 2011 Jan-Feb; 31 (1): 263–80. DOI: 10.1148/rg.311105099. Erratum in: Radiographics. 2011 Mar-Apr;31(2):624. PMID: 21257945.Friedman DN, Lis E, Sklar CA, Oeffinger KC, Reppucci M, Fleischut MH, Francis JH, Marr B, Abramson DH, Dunkel IJ. Whole-body magnetic resonance imaging (WB-MRI) as surveillance for subsequent malignancies in survivors of hereditary retinoblastoma: a pilot study. Pediatr Blood Cancer. 2014 Aug; 61 (8): 1440–4. DOI: 10.1002/pbc.24835. Epub 2013 Nov 1. PMID: 24402721; PMCID: PMC4007376.Friedman DN, Lis E, Sklar CA, Oeffinger KC, Reppucci M, Fleischut MH, Francis JH, Marr B, Abramson DH, Dunkel IJ. Whole-body magnetic resonance imaging (WB-MRI) as surveillance for subsequent malignancies in survivors of hereditary retinoblastoma: a pilot study. Pediatr Blood Cancer. 2014 Aug; 61 (8): 1440–4. DOI: 10.1002/pbc.24835. Epub 2013 Nov 1. PMID: 24402721; PMCID: PMC4007376.Прохоров С.Н., Кочергина Н.В., Рыжков А.Д., Крылов А.С., Блудов А.Б. Сравнение эффективности остеосцинтиграфии, рентгенографии, ОФЭКТ/КТ и МРТ в диагностике метастазов солидных опухолей различной природы в костях. Медицинская радиология и радиационная безопасность. 2022; 67 (6): 74–78.Prokhorov S.N., Kochergina N.V., Ryzhkov A.D., Krylov A.S., Bludov A.B. Comparison of the effectiveness of bone scintigraphy, radiography, SPECT/CT and MRI in the diagnosis of metastases of solid tumors of various origins in bones. Medical Radiology and Radiation Safety. 2022; 67 (6): 74–78. DOI:10.33266/1024-6177-2022-67-6-74-78Messiou C, Hillengass J, Delorme S, Lecouvet FE, Moulopoulos LA, Collins DJ, Blackledge MD, Abildgaard N, Østergaard B, Schlemmer HP, Landgren O, Asmussen JT, Kaiser MF, Padhani A. Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS). Radiology. 2019 Apr; 291 (1): 5–13. DOI: 10.1148/radiol.2019181949. Epub 2019 Feb 26. PMID: 30806604.Messiou C, Hillengass J, Delorme S, Lecouvet FE, Moulopoulos LA, Collins DJ, Blackledge MD, Abildgaard N, Østergaard B, Schlemmer HP, Landgren O, Asmussen JT, Kaiser MF, Padhani A. Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS). Radiology. 2019 Apr; 291 (1): 5–13. DOI: 10.1148/radiol.2019181949. Epub 2019 Feb 26. PMID: 30806604.Zhou M, Lu B, Lv G, Tang Q, Zhu J, Li J, Shi K. Differential diagnosis between metastatic and non-metastatic lymph nodes using DW-MRI: a meta-analysis of diagnostic accuracy studies. J. Cancer Res Clin. Oncol. 2015 Jun; 141 (6): 1119–30. DOI: 10.1007/s00432-014-1895-9. Epub 2014 Dec 17. PMID: 25515409.Zhou M, Lu B, Lv G, Tang Q, Zhu J, Li J, Shi K. Differential diagnosis between metastatic and non-metastatic lymph nodes using DW-MRI: a meta-analysis of diagnostic accuracy studies. J. Cancer Res Clin. Oncol. 2015 Jun; 141 (6): 1119–30. DOI: 10.1007/s00432-014-1895-9. Epub 2014 Dec 17. PMID: 25515409.Donners R, Yiin RSZ, Blackledge M, Koh DM. Whole-body diffusion-weighted MRI of normal lymph nodes: prospective apparent diffusion coefficient histogram and nodal distribution analysis in a healthy cohort. Cancer Imaging. 2021 Nov 27; 21 (1): 64. DOI: 10.1186/s40644021004324. PMID: 34838136; PMCID: PMC8627090.Donners R, Yiin RSZ, Blackledge M, Koh DM. Whole-body diffusion-weighted MRI of normal lymph nodes: prospective apparent diffusion coefficient histogram and nodal distribution analysis in a healthy cohort. Cancer Imaging. 2021 Nov 27; 21 (1): 64. DOI: 10.1186/s40644-021-00432-4. PMID: 34838136; PMCID: PMC8627090.Mytsyk YO, Pasichnyk SM, Kobilnyk YS, Borzhiievskyi OA, Lychkovskyy OE, Kowal P, Pietrus M, Matskevych VM, Dats RI, Blavatska OM, Stakhovskyi OE, Gozhenko AI, Borzhiievskyi AT. Significance of ADC measurements as radiological MRI marker in detection of metastatic lymph node involvement in patients with prostate cancer. Exp Oncol. 2022 Aug; 44 (2): 142–147. DOI: 10.32471/exp-oncology.2312–8852.vol44-no2.17810. PMID: 35964652.Mytsyk YO, Pasichnyk SM, Kobilnyk YS, Borzhiievskyi OA, Lychkovskyy OE, Kowal P, Pietrus M, Matskevych VM, Dats RI, Blavatska OM, Stakhovskyi OE, Gozhenko AI, Borzhiievskyi AT. Significance of ADC measurements as radiological MRI marker in detection of metastatic lymph node involvement in patients with prostate cancer. Exp Oncol. 2022 Aug; 44 (2): 142–147. DOI: 10.32471/exp-oncology.2312–8852.vol44-no2.17810. PMID: 35964652.Marija C, Kresimir D, Ognjen B, Iva P, Nenad K, Matija B. Estimation of colon cancer grade and metastatic lymph node involvement using DWI/ADC sequences. Acta Radiol. 2023 Apr; 64 (4): 1341–1346. DOI: 10.1177/02841851221130008. Epub 2022 Oct 5. PMID: 36197524.Marija C, Kresimir D, Ognjen B, Iva P, Nenad K, Matija B. Estimation of colon cancer grade and metastatic lymph node involvement using DWI/ADC sequences. Acta Radiol. 2023 Apr; 64 (4): 1341–1346. DOI: 10.1177/02841851221130008. Epub 2022 Oct 5. PMID: 36197524.Atallah D, Moubarak M, Arab W, El Kassis N, Chahine G, Salem C. MRI-based predictive factors of axillary lymph node status in breast cancer. Breast J. 2020 Nov; 26 (11): 2177–2182. DOI: 10.1111/tbj.14089. Epub 2020 Oct 18. PMID: 33073463.Atallah D, Moubarak M, Arab W, El Kassis N, Chahine G, Salem C. MRI-based predictive factors of axillary lymph node status in breast cancer. Breast J. 2020 Nov; 26 (11): 2177–2182. DOI: 10.1111/tbj.14089. Epub 2020 Oct 18. PMID: 33073463.Meier-Schroers M, Homsi R, Skowasch D, Buermann J, Zipfel M, Schild HH, Thomas D. Lung cancer screening with MRI: results of the first screening round. J. Cancer Res. Clin. Oncol. 2018 Jan; 144 (1): 117–125. DOI: 10.1007/s00432-017-2521-4. Epub 2017 Sep 20. PMID: 28932985.Meier-Schroers M, Homsi R, Skowasch D, Buermann J, Zipfel M, Schild HH, Thomas D. Lung cancer screening with MRI: results of the first screening round. J. Cancer Res. Clin. Oncol. 2018 Jan; 144 (1): 117–125. DOI: 10.1007/s00432-017-2521-4. Epub 2017 Sep 20. PMID: 28932985.

The authors declare that there are no conflicts of interest present.